免疫疗法和个性化治疗为癌症研究带来了新希望,但是研究者发现,癌症研究正在陷入一个困局:临床试验太多,实验性的癌症药物也太多,但可供试验的病患却不够多。这种僵局的出现,部分是因为药企希望尽快将有利可图的新药推出市场,部分是因为这项药物可能特别有效,但只是对选定的患者有效。7月,美国食品和药物管理局(FDA)准备批准一种开创 Immunotherapy and personalized therapies have brought new hopes for cancer research, but researchers have found that cancer research is in a dilemma: too many clinical trials and too many experimental cancer drugs, but the number of patients available for testing Not enough. This stalemate has arisen in part because pharmaceutical companies hope to market lucrative new drugs as soon as possible, in part because the drug may be particularly effective but only valid for selected patients. In July, the U.S. Food and Drug Administration (FDA) is ready to approve a start-up